GSK
742 hedge funds and large institutions have $9.13B invested in GSK in 2016 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 298 increasing their positions, 238 reducing their positions, and 43 closing their positions.
74% more call options, than puts
Call options by funds: $163M | Put options by funds: $94M
25% more repeat investments, than reductions
Existing positions increased: 298 | Existing positions reduced: 238
23% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 43
0% more funds holding
Funds holding: 742 → 742 (0)
0.08% less ownership
Funds ownership: 3.55% → 3.47% (-0.08%)
3% less capital invested
Capital invested by funds: $9.37B → $9.13B (-$235M)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$61.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$34.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.3M |
| 4 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
+$25.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$155M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$78.1M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$55.3M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$33M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$31.5M |
GSK Hedge Fund Activity: Q3 2016 in Review
742 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2016, worth a combined $9.13B — down 2.5% from $9.37B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new GSK positions and 43 closed out — a net gain of 10 holders — while 298 added to existing stakes and 238 trimmed.
The largest buyer was Grantham, Mayo, Van Otterloo & Co (GMO), adding an estimated $61.8M. The largest seller was JP Morgan Chase, cutting an estimated $155M.
- 742 institutional investors held GSK (GSK) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $9.13B of GSK stock for Q3 2016, down 2.5% quarter-over-quarter.
- 53 funds opened new GSK positions in Q3 2016 and 43 closed out, a net change of +10 holders.
- The largest GSK buyer in Q3 2016 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $61.8M added.
- The largest GSK seller in Q3 2016 was JP Morgan Chase, an estimated $155M sold.
Based on aggregated 13F filings for Q3 2016.